October 30, 2026 Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders Regulatory milestone follows U.S. FDA […]
MitoAction and The POLG Foundation to Co-HostExternally-Led Patient-Focused Drug DevelopmentMeeting on POLG-Related Disorders
October 20, 2026 Virtual PFDD Meeting Scheduled for November 17, 2026 Novi, MI — October 20, 2026 — MitoAction and The POLG Foundation are proud to announce that they will […]
Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders
September 22, 2026 Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders Fast Track Designation adds to recent regulatory momentum for PX578 – […]
Mighty Therapeutics Partners with the POLG Foundation to Develop Novel Preclinical Model for POLG Mitochondrial Disorders and Parkinson’s Disease
September 15, 2026 Trailblazing approach to leverage learnings from rare POLG disorders to inform development for Parkinson’s and other age-related neurological diseases NEEDHAM, Mass., Sept. 15, 2026 /PRNewswire/ — Mighty Therapeutics (the “Company” or […]
Mighty Therapeutics to Develop MYTX-255 for Fatty Acid Oxidation Disorders.
September 9, 2026 New data presented in long-chain fatty acid oxidation disorders at INFORM 2026 support development of Company’s third mitochondrial-targeted candidate NEEDHAM, Mass., Sept. 9, 2026 /PRNewswire/ — Mighty Therapeutics (the “Company” or […]
- 1
- 2
- 3
- …
- 34
- Next Page »













